UCB SA (UCBJF)

OTCMKTS · Delayed Price · Currency is USD

304.29

-1.71 (-0.56%)

At close: Mar 2, 2026

62.92% (1Y)

Market Cap	55.49B
Revenue (ttm)	9.09B
Net Income (ttm)	1.83B
Shares Out	n/a
EPS (ttm)	9.43
PE Ratio	30.34
Forward PE	23.70
Dividend	1.58 (0.52%)
Ex-Dividend Date	Apr 25, 2025

Volume	155
Average Volume	887
Open	304.29
Previous Close	306.00
Day's Range	304.29 - 304.45
52-Week Range	150.70 - 345.39
Beta	0.27
RSI	42.64
Earnings Date	Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1925

Employees 8,600

Stock Exchange OTCMKTS

Ticker Symbol UCBJF

Full Company Profile

Financial Performance

In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.

Financial numbers in EUR Financial Statements

News

UCB SA (UCBJF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Investments ...

UCB SA (UCBJF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Investments Propel Future Prospects

19 hours ago - GuruFocus

Full Year 2025 Ucb SA Earnings Call Transcript

20 hours ago - GuruFocus

Best Income Stocks to Buy for March 2nd

CZNC, UCB and CRI made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 2, 2026.

1 day ago - Nasdaq

UCB SA (UCBJY) Q4 2025 Earnings Call Transcript

3 days ago - Seeking Alpha

UCB SA 2025 Q4 - Results - Earnings Call Presentation

2026-02-27. The following slide deck was published by UCB SA in conjunction with their 2025 Q4 earnings call.

4 days ago - Seeking Alpha

UCB SA Non-GAAP EPS of €9.99, revenue of €7.74B; introduces FY26 outlook

5 days ago - Seeking Alpha

Decoding United Community Banks Inc (UCB): A Strategic SWOT Insight

12 days ago - GuruFocus

Best Income Stocks to Buy for February 12th

WTBA, UCB and RELX made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 12, 2026.

19 days ago - Nasdaq

Best Momentum Stocks to Buy for February 3rd

CX, UCB and TCBI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 2, 2026.

4 weeks ago - Nasdaq

Best Income Stocks to Buy for February 3rd

UCB, BCML and UBSI made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 3, 2026.

4 weeks ago - Nasdaq

UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

6 weeks ago - Seeking Alpha

PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors

The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with...

ARGX ARQT ISRG NVO VRTX

3 months ago - Seeking Alpha

U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with...

4 months ago - PRNewsWire